Form 4: SOPHIA GENETICS CEO Sells Shares Under 10b5-1 Plan

SOPHiA GENETICS SA CEO Jurgi Camblong reported the sale of 8,500 ordinary shares for $5.2354 per share, executed under a pre-arranged trading plan.

Summary

• Jurgi Camblong, CEO of SOPHiA GENETICS SA, sold 8,500 ordinary shares on June 10, 2026.
• The transaction was conducted under a Rule 10b5-1(c) trading plan, indicating it was pre-arranged.
• The weighted average sale price was $5.2354 per share, with individual sales ranging from $5.13 to $5.42.
• Following the transaction, Camblong beneficially owns 3,620,995 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-arranged 10b5-1 plan, which is a standard practice for insider stock transactions.

Negatives

• CEO Jurgi Camblong sold a portion of his shares.
• The sale occurred at a price range of $5.13 to $5.42 per share.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives to diversify holdings or manage personal finances, and are generally not viewed negatively if part of a pre-established plan.

Stakeholder Impact

• Shareholders: The sale by the CEO may be perceived by some shareholders as a negative signal, although the execution under a 10b5-1 plan mitigates this concern.
• Employees: No direct impact on employees is indicated by this transaction.
• Creditors: No impact on creditors is indicated.

Key Dates

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, Share Sale, CEO, Jurgi Camblong